Sunil Gairola | Executive Director
Serum Institute of India Ltd

Sunil Gairola, Executive Director, Serum Institute of India Ltd

Sunil Gairola is the Exécutive Director and Board Member at Serum Institute of India Pvt. Ltd. Experienced in several functions of quality control, quality assurance and clinical bioanalytics of vaccines and biosimilars.  Involved with product development leadership teams for newer vaccines and registration of vaccines in developed and emerging markets. Leads more than 500 scientists working on analytical development and characterization of bacterial, viral, recombinant, sub-unit and viral vector-based vaccines. Collaborator to international initiatives of WHO, NIBSC (MHRA), EDQM, and various Pharmacopoeia aimed at the harmonization of regulatory requirements and development and establishment of international standards. Attended many WHO Consultations for development of Technical Report Series.  Member to scientific body of Indian Pharmacopeia and USP expert panels on vaccines.  Board Member of Developing Countries Vaccine Manufacturers Network (DCVMN).  Served for many years at National Control Laboratory, India.  Association with Accademia as Research guide and authored more than 85 publications and has patents on vaccine development and analytics.   

Appearances:



Day 1 - Tuesday 31st March @ 15:55

Keynote Panel: Resilient, Sustainable, and Decentralized: The Future of Global Vaccine Manufacturing

·       Sustainability in Manufacturing

o   How are manufacturers integrating green technologies? What are the trade-offs between sustainability and cost in LMICs?

·       Regulatory Harmonization & Tech Transfer

o   What frameworks are needed to streamline cross-border approvals? How can WHO, AVAREF, and regional blocs support harmonization?

·       Decentralized & Modular Manufacturing 

o   What are the benefits and limitations of mobile/modular units? How can these models be deployed in outbreak-prone or remote regions?

·       How are different regions evolving?

last published: 11/Mar/26 19:15 GMT

back to speakers